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ABSTRACT
Objective: Rituximab therapy has become a promising therapeutic option for various non-malignant hematological disorders, after being reported 
by many case reports. The objective of this study was to evaluate the immediate, infusion-related adverse drug events (ADE) of patients who received 
rituximab for non-malignant, hematological disorders, in a tertiary healthcare center in India. 
Methods: 14 patients (6 with primary immune thrombocytopenia, 4 with autoimmune hemolytic anemia, 3 with thrombotic thrombocytopenic 
purpura, 1 with acquired hemophilia) were enrolled in the study. Patients were assessable for immediate infusion-related toxicity noted predominately 
within 5 hrs of administration of rituximab infusion. 
Results: Rituximab therapy was tolerated without major ADE. None of the patients experienced high-grade adverse events. The population who 
experienced ADE (Grades 1-2) frequently had toxicities that suspected to result from infusion-related cytokine release syndrome (IRCRS) and 
sometimes required cessation of the infusion and supportive intervention. Patients were monitored for 20 types of ADEs associated with IRCRS. 
11 types of; mild to moderate (Grades 1 and 2) toxicities resulting from IRCRS were experienced by patients. Mean patients who experienced IRCRS 
was 1.95 (13.93%), whereas majority of the study population tolerated therapy without IRCRS (86.78%). Among other toxicities, Grade 2 urinary tract 
infection (UTI) (n=2, 14.29%); Grade 2 hyperglycemia (n=1, 7.14%) and Grade 1 myalgia (n=1, 7.14%) were observed. 
Conclusion: Toxicity profile of patients with non-malignant hematological disorders shows that rituximab is a safer biological therapy.
Keywords:  Rituximab, Infusion related cytokine release syndrome, Adverse drug events, Immediate toxicities, Benign, Non-malignant, Hematological 
disorders.
INTRODUCTION
Rituximab is a chimeric mouse-human monoclonal antibody against the 
CD20 antigen on the surface of B lymphocytes. It binds to CD20 and 
causes B cell death by antibody dependent cell-mediated cytotoxicity, 
complement mediated cytotoxicity and apoptosis. It leads to rapid and 
sustained depletion of B-cells [1]. Although licensed for use in adults 
with CD20 positive B-cell lymphoma and rheumatoid arthritis, it has 
also been used in a variety of off-label indications with promising 
results. It has proved useful as salvage therapy in relapsed/refractory 
non-Hodgkin’s lymphoma and leukemia, and in hematological 
conditions including chronic immune thrombocytopenic purpura, 
hemophilia with inhibitors, and autoimmune hemolytic anemia [2]. 
Rituximab therapy has become a promising therapeutic option for 
various non-malignant hematological disorders, after being reported 
by many case reports. However, the toxicity profiles of rituximab 
among non-malignant hematological disorders were not extensively 
investigated. The objective of this study was to evaluate the immediate, 
infusion-related adverse drug events (ADE) of patients who received 
rituximab for non-malignant, hematological disorders, in a tertiary 
healthcare center in India.
METHODS
This study was undertaken after obtaining permission from Institutional 
Thesis Review Committee. Informed consent to the study was obtained 
from the patients.
Rituximab-related toxicity was assessed during the administration 
of the drug. All 14 patients enrolled in the study were assessable for 
immediate infusion-related toxicity noted predominately within 5 hrs 
of administration of rituximab infusion. The severity of ADE was graded 
according to the National Cancer Institute common terminology criteria 
for adverse events (AE) version 3.0.
Fourteen patients (6 with primary immune thrombocytopenia, 4 with 
autoimmune hemolytic anemia, 3 with thrombotic thrombocytopenic 
purpura, 1 with acquired hemophilia) treated with rituximab were 
evaluated.
RESULTS
Rituximab therapy was tolerated without major ADE. None of the 
patients experienced high-grade AE. The population who experienced 
ADE (Grades 1-2) frequently had toxicities that suspected to 
result from infusion-related cytokine release syndrome (IRCRS) 
and sometimes required cessation of the infusion and supportive 
intervention. Patients were monitored for 20 types of ADEs associated 
with IRCRS.11 types of; mild to moderate (Grades 1 and 2) toxicities 
resulting from IRCRS were experienced by patients. Mean patients 
who experienced IRCRS was 1.95 (13.93%) whereas the majority 
of the study population tolerated therapy without IRCRS (86.78%). 
Among other toxicities, Grade 2 urinary tract infection (UTI) (n=2, 
14.29%); Grade 2 hyperglycemia (n=1, 7.14%) and Grade 1 myalgia 
(n=1, 7.14%) were observed.
DISCUSSION
Patients enrolled in our study demonstrated an acceptable toxicity 
profile with rituximab administration. Adverse effects to rituximab 
can be classified as immediate, acute and delayed. Immediate reactions 
are infusion reactions. Their incidence is about 25% [2]. Despite the 
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However, reactivation of hepatitis B infection, as mentioned by some 
case reports, was not observed in our patients.
CONCLUSION
Toxicity profile of non-malignant hematological disorders treated 
with rituximab reveals that this chimeric monoclonal antibody may 
be a relatively safer biological therapy. Immediate, infusion-related 
toxicities were low grade, without requiring interruption of infusion 
administration. The majority of the observed AE were attributed 
to cytokine release syndrome associated with administration of 
therapeutic monoclonal antibodies.
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fact that rituximab is a safer biological therapy, there were odd reports 
of patients with high-grade AE [3]. In contrast, none of our patients 
experienced any type of high-grade ADE.
Monitoring for ADE among our patients showed that most ADE 
associated with therapy arise due to the development of infusion-
related cytokine release syndrome which was manageable (Table 1). 
The first infusion often causes a syndrome of chills, fever, headache, and 
occasional dyspnea, nausea, pruritis, angiedema, or hypotension [4,5]. 
Although not always mentioned in the different reports, the incidence 
of infusion-related side effects seems to be comparable in immune-
mediated disorders [6]. In the systematic review by Arnold et al., 21.6% 
of the patients showed mild to moderate AE, of which 83.3% were 
infusion-related [7]. Although rare, life-threatening symptoms such as 
bronchospasm, angioedema, hypoxia, and shock have been described. 
However, in our patients’ high-grade toxicities related o IRCRS were not 
observed.
A few patients had moderate grade UTI, hyperglycemia, and myalgia 
(Table 2). Infectious AE reported in post-marketing surveillance 
include an increase in the incidence of UTI by 6%. Musculoskeletal AE 
have been reported with rituximab, although it should be noted that 
myalgia has been associated with reactions related to the infusion 
that can be severe and/or fatal. In clinical trials, AE reported include 
asthenia (26%; 2% combination trials), myalgia (10%), arthralgia 
(10-13%; 6-12% combination trials), and muscle spasms (17%) [1]. 
Table 1: Immediate toxicities in benign hematological disorders









Grade 1 Grade 2 Grades 3‑5 Experienced 
ADE
ADE related to 
IRCRS
1 Shivering 4 (28.6) 0 (0) 0 (0) 4 (28.6)
2 Rashes 0 (0) 2 (14.3) 0 (0) 2 (14.3)
3 Itching 0 (0) 2 (14.3) 0 (0) 2 (14.3)
4 Cough 0 (0) 0 (0) 0 (0) 0 (0)
5 Breathing 
difficulty
1 (7.1) 0 (0) 0 (0) 1 (7.1)
6 Fatigue 1 (7.1) 4 (28.8) 0 (0) 5 (35.7)
7 Dizziness 0 (0) 0 (0) 0 (0) 0 (0)
8 Tachycardia 0 (0) 0 (0) 0 (0) 0 (0)
9 Chest pain 1 (7.1) 0 (0) 0 (0) 1 (7.1)
10 Chills 7 (50) 0 (0) 0 (0) 7 (50)
11 Rigor 3 (21.4) 0 (0) 0 (0) 3 (21.4)
12 Fever 2 (14.3) 2 (14.3) 0 (0) 4 (28.6)
13 Hypotension 0 (0) 0 (0) 0 (0) 0 (0)
14 Rhinitis 5 (35.7) 1 (7.1) 0 (0) 6 (42.9)
15 Dyspnoea 0 (0) 0 (0) 0 (0) 0 (0)
16 Sweating 0 (0) 0 (0) 0 (0) 0 (0)
17 Erythema 0 (0) 0 (0) 0 (0) 0 (0)
18 Throat 
discomfort
4 (28.6) 0 (0) 0 (0) 4 (28.6)
19 Hot flushes 0 (0) 0 (0) 0 (0) 0 (0)
20 Body pain 0 (0) 0 (0) 0 (0) 0 (0)
ADE: Adverse drug events, IRCRS: Infusion related cytokine release syndrome, 
CTCAE: Common terminology criteria for adverse events
Table 2: Immediate toxicities in benign hematological disorders
S. No Toxicity n (%)












21 Nausea 0 (0) 0 (0) 0 (0) 0 (0)
22 Vomiting 0 (0) 0 (0) 0 (0) 0 (0)
23 UTI 0 (0) 2 (14.3) 0 (0) 2 (14.3)
24 Ulcers 0 (0) 0 (0) 0 (0) 0 (0)
25 Blisters 0 (0) 0 (0) 0 (0) 0 (0)
26 Skin peeling 0 (0) 0 (0) 0 (0) 0 (0)
27 Head ache 0 (0) 0 (0) 0 (0) 0 (0)
28 Seizure 0 (0) 0 (0) 0 (0) 0 (0)
29 Hypoglycemia 0 (0) 0 (0) 0 (0) 0 (0)
30 Hyperglycemia 0 (0) 1 (7.1) 0 (0) 1 (7.1)
31 Myalgia 1 (7.1) 0 (0) 0 (0) 1 (7.1)
32 Cyanosis 0 (0) 0 (0) 0 (0) 0 (0)
33 Abdominal 
cramps
0 (0) 0 (0) 0 (0) 0 (0)
ADE: Adverse drug events, UTI: Urinary tract infection, CTCAE: Common 
terminology criteria for adverse events
